



## Syndax Announces Participation at Two Upcoming Investor Conferences

February 26, 2024

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the following sessions at two upcoming investor conferences:

- A fireside chat at TD Cowen's 44<sup>th</sup> Annual Health Care Conference at 9:50 a.m. ET on Monday, March 4, 2024 in Boston, MA
- A corporate panel discussion on leukemia at TD Cowen's 44<sup>th</sup> Annual Health Care Conference at 12:50 p.m. ET on Monday, March 4, 2024 in Boston, MA
- A fireside chat at the Barclays Global Healthcare Conference at 8:30 a.m. ET on Tuesday, March 12, 2024 in Miami, FL

A live webcast of these sessions can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay will also be available for a limited time.

### About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [X \(formerly Twitter\)](#) and [LinkedIn](#).

### Syndax Contacts

Sharon Klahre  
Syndax Pharmaceuticals, Inc.  
[sklahre@syndax.com](mailto:sklahre@syndax.com)  
Tel 781.684.9827

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-302070276.html>

SOURCE Syndax Pharmaceuticals, Inc.